Rekombinanter SARS-CoV-2 Spike S1 Antikörper (RBD)
Kurzübersicht für Rekombinanter SARS-CoV-2 Spike S1 Antikörper (RBD) (ABIN6952547)
Target
Alle SARS-CoV-2 Spike S1 Antikörper anzeigenAntikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
- 
    - 
                                            Highlights
- 
                        - Recombinant human neutralizing antibody (hNAb) against SARS-CoV-2.
- Binds SARS-CoV-2 S proteins of lineages B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.429 (epsilon), and B.1.525 (eta).
- Frequently used as reference in S-protein ELISAs and neutralization assays.
- Synergizes with other hNAbs: binds a highly conserved epitope.
- No interference with the ACE2 binding site.
 
- 
                                            Bindungsspezifität
- RBD
- 
                                            Verwendungszweck
- Recombinant monoclonal antibody to COVID-19 & SARS-CoV S glycoprotein.
- 
                                            Spezifität
- 
                        The chimeric SARS-CoV S1 antibody (CR3022) binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318-510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein (Joyce et al. 2020). While most S-protein RBD binding antibodies compete for antigen binding with ACE2, the CR3022 epitope does not overlap with the ACE2-binding site. It does thus not hinder binding of neutralizing antibodies. While CR3022 on its own exhibits only a weak neutralizing effect, it has been shown to synergize with other S-protein RBD binding antibodies to neutralize SARS-CoV. This effect still has to be confirmed in context with SARS-CoV-2 (Yuan et al. 2020). 
- 
                                            Kreuzreaktivität (Details)
- The anti-SARS-CoV-2 antibody (CR3022) was originally discovered in a SARS patient, but it was shown to be a potent binder of SARS-CoV-2 spike protein (S1).
- 
                                            Produktmerkmale
- 
                        Original Species of Ab: Human Original Format of Ab: IgG1 
- 
                                            Aufreinigung
- Protein A affinity purified
- 
                                            Immunogen
- The original monoclonal antibody was generated through an scFv library derived from a peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
- 
                                            Isotyp
- IgG kappa
 
- 
                                            
- 
    
- 
    - 
                                            Applikationshinweise
- This antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 < a href="https://www.medrxiv.org/content/10.1101/2020.03.17.20037713v1" target="_blank">(Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-ompeting SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020). Bates et al. 2021 (PMID: 32766589) used CR3022 in a immunofluorescence assay.
- 
                                            Kommentare
- 
                        This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. 
- 
                                            Beschränkungen
- Nur für Forschungszwecke einsetzbar
 
- 
                                            
- 
    - 
                                            Format
- Liquid
- 
                                            Konzentration
- 1 mg/mL
- 
                                            Buffer
- PBS with 0.02 % Proclin 300.
- 
                                            Konservierungsmittel
- ProClin
- 
                                            Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 
                                            Lagerung
- 4 °C,-20 °C
- 
                                            Informationen zur Lagerung
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
 
- 
                                            
- 
    - 
                                            : "Highly shape- and size-tunable membrane nanopores made with DNA."    in: Nature nanotechnology, (2022)         (PubMed).        
 : "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody." in: Emerging microbes & infections, Vol. 9, Issue 1, pp. 382-385, (2020) (PubMed).
 : "SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup." in: Current protocols in microbiology, Vol. 57, Issue 1, pp. e100, (2020) (PubMed).
 : "A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV." in: Science (New York, N.Y.), (2020) (PubMed).
 : "Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants." in: PLoS medicine, Vol. 3, Issue 7, pp. e237, (2007) (PubMed).
 
 
- 
                                            : "Highly shape- and size-tunable membrane nanopores made with DNA."    in: Nature nanotechnology, (2022)         (PubMed).        
- 
    - SARS-CoV-2 Spike S1
- 
                                            Substanzklasse
- Viral Protein
- 
                                            Hintergrund
- Spike protein, COVID19, COVID 19, S protein, SARS-CoV S protein, S glycoprotein, E2, Peplomer protein, Spike protein S1, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV, Ab1680.10, Ab1680.15, Ab1680.16
- 
                                            UniProt
- P59594
 Target
- 
                    
 
                                     
                                     
                                    